PMID- 24598452
OWN - NLM
STAT- MEDLINE
DCOM- 20141106
LR  - 20201222
IS  - 1537-4513 (Electronic)
IS  - 1524-9557 (Linking)
VI  - 37
IP  - 3
DP  - 2014 Apr
TI  - T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a 
      phase I/II feasibility and safety study.
PG  - 170-9
LID - 10.1097/CJI.0000000000000031 [doi]
AB  - We report herein the results we obtained and the limitations we experienced 
      during the production and use of a bank of Epstein-Barr virus (EBV)-transformed 
      human cytotoxic T lymphocytes (EBV-CTLs). To assess the feasibility and toxicity 
      of this strategy, we selected and stored, in liquid nitrogen, 4 billion EBV-CTLs 
      from each of the 13 selected donors. Subsequently, in a multicenter phase I/II 
      study, 11 patients with EBV-associated lymphoma resistant to conventional 
      treatments received 1-3 doses of 5 million EBV-CTLs/kg with 1-3 and 0-4 
      compatibilities for human leukocyte antigen (HLA)-I and HLA-II, respectively. 
      Except for one event of fever after injection, no immediate or delayed toxicity, 
      no graft versus host disease, and no graft rejection attributable to CTL infusion 
      were observed. Three patients presented complete remission and 1 partial 
      remission after treatment. Considering the clinical options currently available, 
      and the constrains associated with CTL preparation and implementation, we 
      conclude that CTL banks should consist of a reasonably small number of cell lines 
      with documented specificities. This objective could be more easily achieved if 
      the few homozygous donors for the most frequent HLA alleles of the targeted 
      population could be made available for such a project.
FAU - Gallot, Geraldine
AU  - Gallot G
AD  - *Inserm, U892 daggerCHU Nantes, Hotel Dieu, UTCG double daggerEtablissement Francais du Sang 
      (EFS), Pays de la Loire, Nantes  section signUMR 1098, EFS Bourgogne/Franche-Comte, 
      Bourgogne/Franche-Comte  parallelCHU Limoges, Limoges  paragraph signCHU Bordeaux and University 
      Bordeaux 2, Bordeaux #APHP Hopital Pitie-Salpetriere CHU Pitie Salpetriere **CHU 
      Robert Debre  section sign section signHopital Saint-Antoine, Paris daggerdaggerCHU Brest, Brest double daggerdouble daggerCHU Lilles, 
      Lille, France.
FAU - Vollant, Solene
AU  - Vollant S
FAU - Saiagh, Soraya
AU  - Saiagh S
FAU - Clemenceau, Beatrice
AU  - Clemenceau B
FAU - Vivien, Regine
AU  - Vivien R
FAU - Cerato, Evelyne
AU  - Cerato E
FAU - Bignon, Jean-D
AU  - Bignon JD
FAU - Ferrand, Christophe
AU  - Ferrand C
FAU - Jaccard, Arnaud
AU  - Jaccard A
FAU - Vigouroux, Stephane
AU  - Vigouroux S
FAU - Choquet, Sylvain
AU  - Choquet S
FAU - Dalle, Jean-Hugues
AU  - Dalle JH
FAU - Frachon, Irene
AU  - Frachon I
FAU - Bruno, Benedicte
AU  - Bruno B
FAU - Mothy, Mohamad
AU  - Mothy M
FAU - Mechinaud, Francoise
AU  - Mechinaud F
FAU - Leblond, Veronique
AU  - Leblond V
FAU - Milpied, Noel
AU  - Milpied N
FAU - Vie, Henri
AU  - Vie H
LA  - eng
SI  - ClinicalTrials.gov/NCT01823718
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cell Line
MH  - Child
MH  - Epstein-Barr Virus Infections/immunology/*therapy/virology
MH  - Feasibility Studies
MH  - Female
MH  - Herpesvirus 4, Human/*immunology
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Lymphoma/immunology/*therapy/virology
MH  - Male
MH  - Middle Aged
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Viral Load
MH  - Young Adult
EDAT- 2014/03/07 06:00
MHDA- 2014/11/07 06:00
CRDT- 2014/03/07 06:00
PHST- 2014/03/07 06:00 [entrez]
PHST- 2014/03/07 06:00 [pubmed]
PHST- 2014/11/07 06:00 [medline]
AID - 10.1097/CJI.0000000000000031 [doi]
PST - ppublish
SO  - J Immunother. 2014 Apr;37(3):170-9. doi: 10.1097/CJI.0000000000000031.